Biohealth Innovation
Entrepreneurs who want to pitch their business plan to Steve Case when his Rise of the Rest venture tour comes to Baltimore next month should start preparing now. A pitch competition with a $100,000 prize will be a highlight of the tour’s Sept. 28 stop in Baltimore. The contest starts before entrepreneurs hit the stage — in other cities more than 100 entrepreneurs have applied to the contest. Eight are selected to pitch their business to Case and a panel of local judges.
BioMark Diagnostics Inc. ("BioMark" or the "Company") (CSE:BUX) (FSE:20B), a leader in next-generation diagnostics using metabolites, announces its strategy to expand operations into the U.S. with headquarters in Maryland's world-class biotechnology center. "Expansion of operations into the U.S. market is a critical step in our growth plan," said Rashid Ahmed, BioMark's President and CEO. "This move will support our ability to build upon our leadership position in developing highly sensitive diagnostics that can detect cancer at its very early stages using our proprietary metabolite approach. We are making significant progress in strengthening the clinical validation for our metabolite approach and we are looking to build on the BioMark brand in the U.S. market."
Aeras announced today a new leadership structure for the nonprofit biotech organization with Jacqueline E. Shea, Ph.D., the current Chief Operating Officer (COO), assuming the role of Chief Executive Officer (CEO), effective August 12. Thomas G. Evans, M.D., will step down as CEO to become Acting Chief Scientific Officer (CSO). Ann M. Ginsberg, M.D., Ph.D., will continue as Chief Medical Officer.
Dr. Evans will serve as Acting CSO while Aeras considers how it wishes to fill the position permanently. “I am extremely happy that Dr. Shea will be leading Aeras as we continue our important work of tuberculosis (TB) vaccine development,” said Dr. Evans. “She is an outstanding choice and I am tremendously pleased to know that Aeras leadership will be in her capable hands. This is the right time for me and the organization to make this change, after five years with Aeras first as CSO, then CEO. As Acting CSO, I will be able to focus on the work I most enjoy. There is much unfinished work for me to do in the science arena, and I am looking forward to having the time to concentrate on a number of exciting TB projects.”
Every year, around 8,000 people die waiting for an organ transplant. There just doesn't seem to be enough human organs available for those who need them. Biotech company United Therapeutics has been investigating ways to grow pig organs to be used in humans, and in the four years its researchers have been working on it, the company has become the largest commercial backer of xenotransplantation (transplants between species) and has found some initial success.
Emergent BioSolutions Inc. EBS, -1.75% today announced that the Centers for Disease Control and Prevention (CDC) has exercised options under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin (VIGIV) into the U.S. Strategic National Stockpile. VIGIV is a therapeutic licensed by the U.S. Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination. The contract options, valued at $44 million over two years, will require Emergent to collect plasma for future manufacturing in addition to current collection requirements, conduct manufacturing runs, and conduct additional activities in support of maintaining the FDA licensure of VIGIV.
Roche (ROG.VX) is buying U.S. diagnostics firm GeneWEAVE BioSciences for up to $425 million, expanding the Swiss group's commitment to fighting so-called "superbugs" as the threat from drug-resistant microbes grows.
Roche said on Thursday it would pay shareholders in the privately held Californian company $190 million upfront and up to a further $235 million depending on the future success of its products.
TOPIC: "Innovating through the U.S. Economic Development Administration"
PRESENTER: Julie Lenzer Kirk, Director Office of Innovation and Entrepreneurship U.S. Economic Development Administration
ABSTRACT: Housed within the U.S. Economic Development Administration, the Office of Innovation and Entrepreneurship (OIE) works to foster a more innovative U.S. economy focused on turning new ideas and inventions into products and technologies that spur job growth and competitiveness while promoting economic development. Ms. Kirk will discuss OIE programs including: • Promoting and supporting high-growth entrepreneurship. • Accelerating commercialization of federally funded research. • Working with other agencies and the White House to collaborate on policies and programs to support entrepreneurship and commercialization. • Supporting the National Advisory Council on Innovation and Entrepreneurship (NACIE), which is chaired by the Secretary of Commerce. • Leading the $15 million 2014 Regional Innovation Strategies Program competition.
IBM says that Watson, its artificial-intelligence technology, can use advanced computer vision to process huge volumes of medical images. Now Watson has its sights set on using this ability to help doctors diagnose diseases faster and more accurately.
Last week IBM announced it would buy Merge Healthcare for a billion dollars. If the deal is finalized, this would be the third health-care data company IBM has bought this year (see “Meet the Health-Care Company IBM Needed to Make Watson More Insightful”). Merge specializes in handling all kinds of medical images, and its service is used by more than 7,500 hospitals and clinics in the United States, as well as clinical research organizations and pharmaceutical companies. Shahram Ebadollahi, vice president of innovation and chief science officer for IBM’s Watson Health Group, says the acquisition is part of an effort to draw on many different data sources, including anonymized, text-based medical records, to help physicians make treatment decisions.
Announcing the Buzz of BIO: Recognizing the most innovative companies at the 2015 BIO Investor Forum™
Are you an early-stage company looking for your next financing round, or a late-stage private company hoping to make the valuable connection needed to take your product to the next phase? Nominate your company to be the Buzz of BIO at this year's BIO Investor Forum.
Winners receive complimentary conference registration, a Company Presentation and promotion to industry leaders including a spotlight in BioCentury Extra.
A new analysis of data from the 2012 National Health Interview Survey (NHIS) has found that most American adults have experienced some level of pain, from brief to more lasting pain, and from relatively minor to more severe pain. The analysis helps to unravel the complexities of a Nation in pain. It found that an estimated 25.3 million adults (11.2 percent) had pain every day for the preceding 3 months. Nearly 40 million adults (17.6 percent) experience severe levels of pain. Those with severe pain are also likely to have worse health status. The analysis was funded by the National Institutes of Health’s National Center for Complementary and Integrative Health (NCCIH) and was published in The Journal of Pain.
Gliknik Inc., a privately held biopharmaceutical company, today announced that its licensee Pfizer Inc. (NYSE: PFE) has received notification from the U.S. Food and Drug Administration (FDA) that its autoimmune candidate drug GL-2045, a recombinant Intravenous Immune Globulin (IVIG)-mimetic, has been granted orphan drug designation for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). CIDP is a rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms.
You can now use 3D printing to create items using a wide range of filaments, and not just plastics. Metals, edibles, bio and construction materials are just some of the examples that are being developed for 3D printing.
So it shouldn’t come as a surprise when the U.S. Food and Drug Administration (FDA) approved Spritam, an epilepsy medication made using 3D printers.
Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, and BioChain, an early cancer diagnostic company with operations in both USA and China and Epigenomics' exclusive strategic commercialization partner in China, today announced that testing based on the proprietary Septin9 biomarker was included in the Chinese Guideline on Screening, Endoscopic Diagnosis and Treatment of Early Colorectal Cancer (CRC).
Gaithersburg-based biotech MedImmune entered an exclusive license agreement to work on vaccines targeting cancers caused by human papillomavirus, or HPV.
Under the agreement, announced Monday, MedImmune — the biologics research and development arm of U.K. pharmaceutical giant AstraZeneca (NYSE: AZN) – will collaborate with immunotherapy company Inovio Pharmeuticals. Inovio's "INO-3112" immunotherapy generates killer T-cell responses to destroy tumors associated with HPV. It is in Phase I and II clinical trials for cervical, head and neck cancers.
Bye bye, ‘burbs. Vasoptic Medical is officially a city company now.
The medical device startup, which is making a device that allows primary-care doctors to give diabetes patients eye exams rather than making an extra trip to the eye doctor, completed its move from Columbia to Locust Point. The company’s new office is within Mindgrub’s climbing-wall-outfitted space near McHenry Row.
Mobile health tools will be “a powerful equalizer” in terms of geographic health disparities, according to executives from the Aetna Foundation.
Aetna Foundation leaders Dr. Garth Graham, MaryLynn Ostrowski and Alyse Sabina said in a post on the Health Affairs blog:
Secretary of Commerce Penny Pritzker announced the launch of the Economic Development Administration's (EDA) 2015 Regional Innovation Strategies (RIS) Program competition to spur innovation capacity-building activities in regions across the nation. Under the 2015 announcement, SBA will commit $10 million for two funding opportunities:
In response to a request from the Congress, NIH is developing a 5-year NIH-wide Strategic Plan to advance its mission to support research in pursuit of fundamental knowledge about the nature and behavior of living systems, and the application of that knowledge to extend healthy life and reduce illness and disability. Senior leadership and staff from all 27 Institutes, Centers, and Offices (ICOs) are contributing to the proposed direction and content of the Strategic Plan, with input from the Advisory Committee to the Director, NIH. The framework below identifies crosscutting areas of research exemplifying the breadth of ICOs' priorities and aims to outline a set of unifying principles to guide NIH in pursuit of its mission. The goal of this larger NIH-wide strategic plan is not to outline the myriad of important research opportunities for specific disease applications (as that is covered in the strategic plans from each of the ICOs, which will be referenced appropriately), but to highlight major trans-NIH themes. The Strategic Plan is due to the Congress in late December 2015.
Positive results of Symbiomix Therapeutics' first pivotal trial for lead drug candidate SYM-1219, a single-dose, oral product candidate for the treatment of bacterial vaginosis (BV), were presented today at the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting in Portland, Oregon. The results from the multi-center, randomized Phase 2 trial showed that a single oral dose of SYM-1219 met the trial's primary endpoint of Clinical Outcome Responder and was well tolerated for the treatment of BV. Based on discussions with the U.S. Food and Drug Administration (FDA) at an End-of-Phase 2 meeting, the Company plans to submit the Phase 2 trial as one of two pivotal studies for a New Drug Application (NDA). A second pivotal trial of SYM-1219 is currently enrolling patients, with targeted completion by the end of 2015. If the second pivotal trial is successful, an NDA could be submitted in mid-2016.
Originally the national headquarters for WIB, the "Washington DC/Baltimore" chapter officially became its own chapter in October 2011. Located along the I-270 Corridor in Maryland and also covering DC, Northern Virginia and the greater Baltimore area, this setting is central to what Governor Martin O’Malley called, "one of the largest bioscience clusters in the nation, perhaps in the world."
The WIB-Washington DC/Baltimore Chapter community is dedicated to creating opportunities and careers for women in the life science industry and to encouraging women in our region to translate novel discoveries into products. Our chapter symbolizes the significance of promoting the dynamic women in the biotechnology and life sciences industry in this area and globally. Our membership consists of professionals at leading pharmaceutical, biotechnology, device and diagnostics companies, non-profits, academic institutions, and support service companies, including law firms, consultants, and financial service firms.
MedImmune, a global biologics R&D arm of AstraZeneca, has entered into an exclusive clinical trial collaboration with Mirati Therapeutics, US-based oncology firm focusing on genetic and epigenetic drivers of cancer.
As part of the deal, a Phase I/II trial will be conducted to evaluate the safety and efficacy of MedImmune's durvalumab (MEDI4736) in combination with Mirati's mocetinostat in patients with non-small cell lung cancer (NSCLC), with the potential to explore additional indications in the future.
Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized management to pursue a tax-free spin-off of the company's Biosciences business into a separate, stand-alone publicly-traded company. The spin-off is expected to create two independent public companies with distinct strategic plans, growth strategies, and operational and development priorities.
The new Biosciences company, to be named at a later date, will focus on providing novel oncology and hematology therapeutics to meaningfully improve patients' lives. The core technology of the Biosciences company will be its ADAPTIR platform applied to immuno-oncology. Emergent BioSolutions will continue to operate as a global specialty biopharmaceutical company whose core business is focused on providing specialty products for civilian and military populations that address intentional and naturally emerging public health threats.
GSK and Save the Children have launched their third annual $1 million healthcare innovation award that rewards innovations in healthcare that have helped to reduce child deaths in developing countries.
Organisations from across developing countries can nominate examples of innovative health approaches they have implemented till September 7, 2015. These approaches must have resulted in tangible improvements to under five child survival rates, be sustainable and have the potential to be scaled-up and replicated.
Ever heard of a hospital setting up a digital health operation within a single center of excellence? We hadn’t, either, until this week, when the Temple Lung Center at Temple University Health System in Philadelphia announced the establishment of the Center for Digital Health.
Dr. Gerard Criner, founding chair of Temple’s Department of Thoracic Medicine and Surgery, which started up in February, leads the Center for Digital Health. He also founded and continues to serve as chairman of HGE Health Care Solutions, a Temple spinoff that has built a mobile app that helps clinicians manage patients with chronic obstructive pulmonary disorder.
Illumina, Inc. ILMN, today announced Illumina Accelerator—the world’s first business accelerator focused solely on creating an innovation ecosystem for the genomics industry—has selected three new startups for its second funding cycle. Selected from a competitive pool of highly qualified applicants, the new startups from across the globe are spurring genomics innovation in healthcare, agriculture, and the winemaking industry.
Apparently, requiring scientists to state their objectives ahead of time makes a big difference.
Around 2000, the U.S. government ordered researchers conducting clinical trials with federal money to announce ahead of time which medical question they were hoping to answer.
We told you Tuesday about the first-ever White House demo day on Tuesday, which featured 32 early- to growth-stage companies sharing their personal stories and demonstrating their technologies.
And now, some prizes: Six Greater Washington accelerators were awarded prizes from the Small Business Administration, the SBA announced. It was part of a $4.4 million national program encouraging entrepreneurship, according to the SBA.
This paper is a final project from the NIH Foundation for Advanced Education in the Sciences course — TECH 566: Biotechnology Management
Starting up a company is a risky endeavor. From listening to the FAES 566’s course panel discussions this semester, it is clear that there are many challenges a Chief Executive Officer (CEO) will face and try to overcome while starting up and exiting his/her company. Fortunately, we also learned that there are numerous resources available to assist new entrepreneurs in developing strategies for management, funding, technology transactions, and approaches to exit, to name a few.
Blood is one of those things Americans take for granted.
Here, when patients are rushed to the hospital after an accident and are losing a lot of blood, we assume the hospital will have units of donated blood ready to hook up when the ambulance arrives. We don’t think about how much each unit of blood costs — yes, it has a price — because we have health insurance that pays the bill.
After 10 years as a successful veterinarian, Ignacio "Nacho" Pino decided to dedicate himself to work that could bring state-of-the-art biotechnology research to his home of Puerto Rico.
CDI Laboratories—a company he founded in 2008 along with Johns Hopkins University researchers Heng Zhu and Seth Blackshaw, JHU professor emeritus Jef Boeke, and two others (Dan Eichinger and Joe Bonaventura)—aims to produce research-grade protein and antibody products that support scientific research on cancer, autoimmunity, and infectious diseases. The company is one of more than 30 startups being showcased in Washington, D.C., today as part of the first-ever White House Demo Day, which will highlight the work of a diverse group of entrepreneurs from across the country.
Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
Notices:
Program Announcements:
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
AstraZeneca Plc and Isis Pharmaceuticals Inc. will work together, expanding an earlier collaboration, to seek gene therapy treatments for diseases affecting the heart, kidneys and the body’s metabolism.
AstraZeneca agreed to pay Isis an upfront fee of $65 million plus development and regulatory milestones for each program that the London-based drugmaker advances to clinical development, the companies said in a statement. Isis, based in Carlsbad, California, will earn tiered double-digit royalties on annual sales of each program.
During a tour to Paris, Bruce Springsteen explained that his dream was for the US to adapt a Swedish style welfare state. The famous musician is far from alone in idealizing Nordic policies. The four Nordic nations (Denmark, Finland, Norway and Sweden) are often regarded as prime role-models the policies to be emulated by others. Internationally, advocates of left of centre policies view these countries as examples of how high tax social democratic systems are viable and successful. Paul Krugman, for example, has said: “Every time I read someone talking about the ‘collapsing welfare states of Europe’, I have this urge to take that person on a forced walking tour of Stockholm”.
Baltimore will be the first stop for billionaire investor and entrepreneur Steve Case, who in September kicks off a $1 million investment round.
Case, CEO of the Washington, D.C., venture firm Revolution, plans to invest $1 million in startups in cities that are off the beaten path for most venture capitalists. The Rise of the Rest bus tour kicks off Sept. 28 in Baltimore and will make stops in Philadelphia, Buffalo and Manchester and Portland, Maine.
Today Startup Maryland announced updates to the schedule (September 12 - October 2) and the rough route for the Pitch Across Maryland, the fourth annual state-wide tour and celebration of entrepreneurship and high-growth startup companies.
The Pitch Across Maryland tour will again traverse the state all in the name of celebrating Maryland's diverse communities of venture building. A sampling of details, key data and results from previous tours follow: